The impact of patient-related nonmodifiable factors on perioperative outcomes following radical cystectomy with enhanced recovery protocol

Daniel Zainfeld, Jian Chen, Jie Cai, Gus Miranda, Anne Schuckman, Siamak Daneshmand and Hooman Djaladat

Abstract

Background: Enhanced recovery after surgery (ERAS) protocols decrease the length of hospital stay (LOS) and complications following radical cystectomy (RC). However, the impact of non-modifiable patient factors to postoperative outcome is unclear. This study aimed to identify nonmodifiable patient and disease factors predictive of post-RC outcomes with ERAS protocols.

Methods: We reviewed our institutional review board-approved prospectively maintained bladder cancer database. Patients with primary urothelial bladder cancer who underwent open RC with ERAS protocol between 2012 and 2016 were identified. Patient demographic and disease-relevant variables were reviewed. Factors predictive of LOS, 30- and 90-day complications and readmission were assessed using univariate and multivariable analyses.

Results: A total of 289 patients with a median age of 70 years were included, of whom 80.6% were male, 33.6% had Charlson comorbidity index ≥2. Median LOS was 4 days and 21.1% received intraoperative transfusion. The 30-day complication and readmission rates were 58.8% and 16.6%, respectively. Age >70 (p = 0.02), Charlson comorbidity index ≥2 (p = 0.005), and intraoperative transfusion (p = 0.03) were significantly associated with LOS. Intraoperative transfusion was significantly associated with 30-day complication and readmission (p = 0.008, p = 0.005, respectively). No factor was found to be significantly associated with 90-day complication or readmission.

Conclusions: With ERAS protocol, non-modifiable patient and disease factors influence outcomes after RC. Risk adjustment for these factors is important for patient counseling, quality assessment and future reimbursement.

Keywords: cystectomy, patient readmission, postoperative complications, urinary bladder neoplasms

Introduction

Fast-track or enhanced recovery after surgery (ERAS) protocols have been developed to improve perioperative outcomes by addressing issues relevant to surgical performance and recovery in a multimodal multidisciplinary approach. These techniques have proven successful and have been implemented across virtually all surgical disciplines. Within the field of urology, radical cystectomy (RC) has been most targeted for application of ERAS principles due to significant associated morbidity, lengthy postoperative hospitalizations, and high rates of complications and readmission. Applying ERAS protocols among patients undergoing RC has resulted in shortened length of stay (LOS) and decreased gastrointestinal-related complications without significantly impacting complication rates or hospital readmission. In a contemporary evaluation of outcomes following open radical cystectomy (ORC),
postoperative LOS was decreased to median 4 days versus 7 days prior to ERAS implementation, and similar benefits have been demonstrated at additional centers.\textsuperscript{3,5,6}

Nonetheless, RC remains one of the most challenging urological procedures. Beyond the inherent complexity of the procedure, bladder cancer is most prevalent among older patients with multiple comorbidities.\textsuperscript{7,8} Postoperative complications occur in 28–64\% and are noted to be even higher when limited to elderly populations.\textsuperscript{8–10} Current studies on ERAS highlight the role of perioperative care in determining outcomes and emphasize the value of consistent and standardized care.\textsuperscript{11–13} However, the impact of nonmodifiable patient factors is more difficult to assess in the context of these confounding factors.

Our institution performs a high volume of RC annually and has a well-established ERAS protocol in which patient care is highly standardized at all levels. In this study, we sought to examine the impact of individual nonmodifiable as well as surgical-related factors among patients undergoing RC in the setting of ERAS to better characterize their role in driving postoperative outcomes.

Materials and methods

Study population

Patients with primary urothelial bladder cancer undergoing ORC, urinary diversion, and bilateral extended pelvic lymph node dissection at our institution by three fellowship-trained urologic oncologists from May 2012 to March 2016 were identified from our institutional review board-approved intent-to-cure bladder cancer database.

ERAS protocol

An institutional ERAS protocol was implemented in May 2012 for all consecutive patients. This protocol has been described previously and includes preoperative, intraoperative, and postoperative components;\textsuperscript{3} preoperatively, patients have no bowel preparation but high-protein, high-carbohydrate liquid drinks. Intravenous antibiotics start just before surgery and continue for 24h postoperatively. After the first 24h, the patient is transitioned to oral suppressive antibiotics. Fluid intake is minimized intraoperatively after clipping the ureters, with careful monitoring of intravascular fluid volume. If a nasogastric tube was placed preoperatively, it is removed at the end of surgery. On the night of the surgery, patients are started on a clear liquid diet. If tolerated well, they proceed to a regular diet on postoperative day (POD) 1. Patients receive a cholinergic drug (neostigmine) and \(\mu\)-opioid receptor antagonist (alvimopan) until the first bowel movement.

Discharge and follow up

Discharge criteria following ORC include adequate oral intake (over 1 L/day), bowel movement, pain control and expected laboratory values. Patients are discharged with oral prophylactic antibiotics, deep vein thrombosis prophylaxis and supportive intravenous hydration given by home health nurses every other day for 3 weeks. Postoperative visits are scheduled at 1, 3, 6 and 12–16 weeks.\textsuperscript{3}

Data collection and analysis

Patient data were captured prospectively by a research operator (GM), including demographics such as age, gender and body mass index (BMI), as well as clinical factors including Charlson comorbidity index (CCMI), American Society of Anesthesiologists (ASA) score and surgical-related factors, such as estimated blood loss (EBL), diversion type and pathology. Postoperative complications were graded according to Clavien–Dindo classification. Clavien–Dindo grades I and II were considered as minor complications; grades III–V were considered as major complications.

Statistical software package SAS\textsuperscript{\textregistered}, version 9.4 (SAS Institute Inc., Cary, NC, USA) was applied to all analysis in this study. Pearson’s Chi-square or Fisher’s exact tests were used to examine categorical variables. The Kruskal–Wallis test was used to evaluate continuous variables. A stepwise linear regression was used to identify factors associated with LOS. A stepwise logistic regression was used to identify independent predictors of 30- and 90-day readmission and complications. All \(p\)-values reported are two-sided, with \(p < 0.05\) considered statistically significant.

Results

A total of 289 consecutive patients were included in this study. Patient demographics, disease characteristics, surgical data and postoperative outcomes are demonstrated in Table 1. Median patient age was 70 years (range 38–91). The majority of patients were male (80.6\%).
Table 1. Patient demographics, disease characteristics, surgical data and postoperative outcomes ($n = 289$).

| Patient demographics | | |
|----------------------|-----------------|---|
| Median age (range)   | 70              | [38–91] |
| Age $\leqslant$ 70, $n$ (%) | 150             | [51.9] |
| Age $> 70$, $n$ (%)    | 139             | [48.1] |
| Gender, $n$ (%)       | | |
| Male                 | 233             | [80.6] |
| Female               | 56              | [19.4] |
| Median BMI (range)    | 27.3            | [17.8–42.2] |
| Charlson comorbidity index, $n$ (%) | | |
| 0                    | 122             | [42.2] |
| 1                    | 70              | [24.2] |
| $\geqslant$ 2        | 97              | [33.6] |
| Neoadjuvant chemotherapy, $n$ (%) | 97             | [33.6] |
| Prior pelvic radiation, $n$ (%) | 8              | [2.8] |

| Disease characteristics and surgical data | | |
| Pathological T stage, $n$ (%) | | |
| $\leqslant$ T2              | 185             | [64] |
| $\geqslant$ T3              | 104             | [36] |
| Pathological N stage, $n$ (%) | | |
| $\geqslant$ N1              | 57              | [19.7] |
| Diversion type, $n$ (%)     | | |
| Orthotopic neobladder       | 188             | [65] |
| Continent cutaneous diversion | 19            | [6.6] |
| Ileal conduit               | 82              | [28.4] |
| Median baseline hemoglobin (range) | 11.8           | [6.3–17.8] |
| Intraoperative transfusion, $n$ (%) | 61              | [21.1] |

| Postoperative outcomes | | |
| Length of stay, median (range) | 4              | [3–41] |
| 30-day minor complication, $n$ (%) | 139           | [48.1] |
| 30-day major complication, $n$ (%) | 31             | [10.7] |
| 30-day readmission, $n$ (%)       | 48             | [16.6] |
| 90-day minor complication, $n$ (%) | 158            | [54.7] |
| 90-day major complication, $n$ (%) | 62             | [21.4] |
| 90-day readmission, $n$ (%)       | 89             | [30.8] |

BMI, body mass index.
The median LOS was 4 days (range 3–41). Minor and major complication rates at 30 days were 48.1% and 10.7%, respectively. Minor and major complication rates at 90 days were 54.7% and 21.4%, respectively. Readmission rates at 30 days and 90 days were 16.6% and 30.8%, respectively.

### Length of stay

On univariate linear regression, significant associations with LOS were identified for age > 70 (p < 0.001), CCMI ≥ 2 (p = 0.004), clinical stage ≥ cT2 (p = 0.03), nonorthotopic urinary diversion (p < 0.001), and intraoperative transfusion (p = 0.007) (Table 2). On multivariable linear regression, age > 70 (p = 0.02), CCMI ≥ 2 (p = 0.005), and intraoperative transfusion (p = 0.03) remained significant associations with LOS (Table 2). Parameter estimates (β) for each of these variables were greater than 1, indicating at least one additional day of hospitalization dependent on that variable.

### 30- and 90-day complications and readmissions

Patients experiencing complications within 30 days postoperatively had lower baseline hemoglobin (HGB) levels (11.4 versus 12.0 g/dl, p = 0.04), higher intraoperative transfusion rate (26.5 versus 13.5%, p = 0.008) and longer LOS (5 versus 4 days, p < 0.001) (Table 3). Similarly, patients readmitted within 30 days postoperatively had lower baseline HGB levels (11.1 versus 11.9 g/dl, p = 0.05) and higher intraoperative transfusion rate (37.5 versus 18.7%, p = 0.006) (Table 4). No significant differences were identified with gender, BMI, ASA score, pathologic stage, diversion type, receipt of neoadjuvant chemotherapy, age or CCMI regarding 30-day complications or readmission. Multivariable logistic regression revealed a significant association between intraoperative transfusion and 30-day complications [odds ratio (OR) 2.32; 95% confidence interval (CI) 1.24–4.34; p = 0.009]. Patients receiving intraoperative transfusion were also significantly more likely to be readmitted within 30 days (OR 2.76; 95% CI 1.41–5.4;

### Table 2. Univariate and multivariable linear regression model of nonmodifiable factors impacting length of stay.

| Factors                              | β (days) | 95% confidence interval | p value |
|--------------------------------------|----------|-------------------------|---------|
| **Univariate**                       |          |                         |         |
| Age > 70                             | 1.56     | 0.66–2.47               | <0.001  |
| ASA score 3–4                        | 0.88     | −0.23–2.01              | 0.120   |
| Charlson comorbidity index ≥ 2       | 1.38     | 0.45–2.30               | 0.004   |
| Clinical stage ≥ T2                  | 1.31     | 0.10–2.53               | 0.030   |
| Diabetes                             | −0.16    | −1.29–0.98              | 0.790   |
| Female gender                        | −0.19    | −0.33–0.74              | 0.740   |
| Neoadjuvant chemotherapy             | −0.64    | −1.62–0.34              | 0.200   |
| Nonorthotopic diversion              | 1.83     | 0.89–2.78               | <0.001  |
| Pathologic stage ≥ T2                | 0.71     | −0.28–1.71              | 0.160   |
| Intraoperative transfusion           | 1.55     | 0.43–6.79               | 0.007   |
| **Multivariable**                    |          |                         |         |
| Age > 70                             | 1.1      | 0.18–2.02               | 0.020   |
| Charlson comorbidity index ≥ 2       | 1.57     | 0.49–2.66               | 0.005   |
| Intraoperative transfusion           | 1.19     | 0.09–2.28               | 0.030   |

ASA, American Society of Anesthesiologists.
No significant associations were found between variables of interest and 90-day readmission or complications in univariate or multivariate analyses (data not presented).

**Discussion**

Bladder cancer is a serious urological malignancy in the United States, with more than 79,000 new diagnoses and over 16,800 deaths estimated in 2017. Although RC is considered the gold standard treatment for muscle invasive bladder cancer, it is associated with considerable morbidity. The trends toward care standardization after RC have been driven by widespread introduction and utilization of ERAS protocols along with the demonstrated value of care centralization at high-volume centers of excellence. Cost constraints and an ongoing shift from volume-based to value-based care have served to incentivize institutions and providers to limit expenditures by improving quality in the form of decreased postoperative LOS and minimizing perioperative complications.

Overall effects of these approaches remain to be determined as reimbursement models continue to evolve. Despite recent successes in improving

---

### Table 3. Demographics and surgical data of patients with and without complications within postoperative day 30.

| Characteristics                             | With complications | Without complications | p value |
|---------------------------------------------|--------------------|-----------------------|---------|
| **n = 170**                                 | **n = 119**        |                       |         |
| **With complications**                      | **Without complications** | **p value** |
| Age > 70, n [%]                             | 87 (51.2)          | 52 (43.7)             | 0.230   |
| Male gender, n [%]                          | 131 (77.1)         | 102 (85.7)            | 0.070   |
| BMI, median [range]                         | 27.2 (17.3–40)     | 26.5 (18.3–41.7)      | 0.420   |
| Charlson comorbidity index >= 2, n [%]      | 62 (36.5)          | 35 (29.4)             | 0.420   |
| **Baseline laboratory, median, [range]**   |                    |                       |         |
| Alb [g/L]                                   | 39 [31–50]         | 40 [33–53]            | 0.280   |
| HCT                                         | 34.4 [19.6–50.3]   | 36.2 [22–53.3]        | 0.080   |
| HGB [g/dl]                                  | 11.4 [6.3–17.0]    | 12.0 [7.3–17.8]       | 0.040   |
| **Clinical T stage >= T3, n [%]**           | 30 (16.7)          | 20 (16.8)             | 0.880   |
| **Clinically positive nodal disease, n [%]**| 13 (7.6)           | 8 (6.7)               | 0.910   |
| **Neoadjuvant chemotherapy, n [%]**         | 56 [32.9]          | 41 [34.5]             | 0.800   |
| **Surgery**                                 |                    |                       |         |
| EBL, ml, median [range]                     | 500 [100–2500]     | 400 [100–1800]        | 0.090   |
| Intraoperative transfusion, n [%]           | 45 [26.5]          | 16 [13.5]             | 0.008   |
| Diversion type, n [%]                       |                    |                       | 0.100   |
| Orthotopic                                  | 104 [61.2]         | 84 [70.6]             |         |
| Nonorthotopic                               | 66 [38.8]          | 35 [29.4]             |         |
| Length of stay, days [range]                | 5 [3–41]           | 4 [3–39]              | <0.001  |

BMI, body mass index; EBL, estimated blood loss; HCT, hematocrit; HGB, hemoglobin.

*p = 0.003*. No significant associations were found between variables of interest and 90-day readmission or complications in univariate or multivariate analyses (data not presented).
outcomes such as LOS through ERAS protocols, the role of individual patient factors and of surgical variables must be appreciated to facilitate improved counseling and perioperative planning/management, and to inform assessments of quality. Knowing the impact of nonmodifiable factors on LOS, providers can modify preoperative patient counseling regarding expectations and potential alterations to care plans that may enhance patient and family experience and reported outcome. Nonmodifiable factors have been assessed in the setting of renal surgery determining association of older age, African American race, greater ASA score and social insurance status with discharge quality.\textsuperscript{18} Another study found higher CCMI and nephrometry score associated with longer LOS following robotic-assisted partial nephrectomy.\textsuperscript{19}

In the current study, the impact of nonmodifiable and surgical-related factors on perioperative outcomes was evaluated in the context of a standardized surgical approach performed by three fellowship-trained urologic oncologists with an established ERAS pathway. We included only ORC cases in this study to prevent eluding of data and to maintain the homogeneity of the cohort, so that we have a better understanding of the effect

| Characteristics                                      | With readmission | Without readmission | p value |
|------------------------------------------------------|------------------|---------------------|---------|
| Age > 70, n (%)                                      | 27 (56.2)        | 112 (46.5)          | 0.270   |
| Male gender, n (%)                                   | 36 (75)          | 197 (81.7)          | 0.320   |
| BMI, median (range)                                  | 26.9 (17.3–40)   | 26.8 (17.9–41.7)    | 0.740   |
| Charlson comorbidity index ≥2, n (%)                 | 18 (37.5)        | 79 (32.8)           | 0.750   |
| Baseline laboratory, median (range)                  |                  |                     |         |
| Alb (g/L)                                            | 40 (31–50)       | 39 (32–53)          | 0.310   |
| HCT                                                  | 33.8 (19.6–46.7) | 35.9 (21.2–53.3)    | 0.090   |
| HGB [g/dl]                                           | 11.1 (6.3–15.7)  | 11.9 (7.0–17.8)     | 0.050   |
| Clinical T stage ≥ 3, n (%)                          | 8 (16.7)         | 42 (17.4)           | 1.000   |
| Clinically positive nodal disease, n (%)             | 5 (10.4)         | 16 (6.6)            | 0.610   |
| Neoadjuvant chemotherapy, n (%)                       | 18 (37.5)        | 79 (32.8)           | 0.620   |
| Surgery                                              |                  |                     |         |
| EBL, ml, median, (range)                             | 500 (200–1500)   | 450 (100–2500)      | 0.320   |
| Intraoperative transfusion, n (%)                    | 18 (37.5)        | 43 (17.8)           | 0.006   |
| Diversion type, n (%)                                |                  |                     | 0.620   |
| Orthotopic                                           | 33 (68.8)        | 155 (64.3)          |         |
| Nonorthotopic                                        | 15 (31.2)        | 86 (35.7)           |         |
| Length of stay, days (range)                         | 5 (3–16)         | 4 (3–41)            | 0.100   |

ASA, American Society of Anesthesiologists; BMI, body mass index; EBL, estimated blood loss; HCT, hematocrit; HGB, hemoglobin.
of these factors without the confounding effect of the surgical approach. By limiting our analysis to ORC with ERAS, we have also minimized the confounding effect of a minimally invasive approach on assessment of variables of interest.

We looked at nonmodifiable demographic factors such as age and gender, as well as clinically and surgically relevant factors such as preoperative HGB, receipt of intraoperative transfusion and EBL. Defining factors as modifiable or nonmodifiable is important for future potential efforts toward preoperative risk modification. Some factors such as BMI must therefore be evaluated in the context of planned treatment to determine status as nonmodifiable. Given known negative consequences of delay of cystectomy, many factors were deemed nonmodifiable, though they may clearly be modified given adequate resources in the absence of time constraints. Identification of specific predictive factors and determination of capacity for modification is essential and is the topic of ongoing research where factors such as mental health and sarcopenia have been linked to perioperative outcomes from RC. Among the limitations of these studies is an inability to delineate the potential role of perioperative care in compensating for or modifying the impact of the factors of interest. Also in this study, with regards to LOS, we observed that patient age > 70, and increased comorbidity index (CCMI ≥ 2) were each associated with at least one additional day of hospitalization. The role of perioperative complications on LOS has been well-reported, with postoperative ileus the most common cause for extended hospitalization. However, ERAS pathways and opioid receptor antagonists have greatly lessened gastrointestinal complications following cystectomy. Factors contributing to LOS within an optimized ERAS protocol have therefore not been well-described.

A recent review of Medicare beneficiaries undergoing major surgical interventions found early discharge to be associated with lower total payments per episode, which were not offset by higher subsequent spending, suggesting earlier discharge possible serves to minimize expenditures. However, a study evaluating patients undergoing RC at a single institution prior to ERAS implementation found LOS ≤ 5 days to be associated with a significant independent increase in risk of major outpatient complication [hazard ratio (HR) 1.91; 95% CI 1.03–3.56; p = 0.04], and increased risk of readmission (HR 1.60; 95% CI 1.01–2.44; p = 0.048). Therefore, optimizing LOS following RC is not clear and likely varies by individual patient, dependent on a variety of factors in whom anticipated costs must be balanced with distinct patient risk. Ability for providers to modify preoperative patient counseling regarding expectations and potential alterations to care plans will carry direct implications for patient and family experience as well as patient-reported outcomes, an increasingly important consideration in modern healthcare delivery.

Finally, variable outcomes carry direct implications for reimbursement with increased LOS, readmissions, and complications associated with weighty financial consequences. In an era of ongoing healthcare reform, bundled care is among the proposed strategies to improve value and is being actively explored in selected settings. By providing global reimbursement for a procedure and associated perioperative care, provider incentives are better aligned with quality; that is, limiting perioperative complications, LOS and readmissions. Hence, differentiating modifiable and nonmodifiable factors affecting these outcomes will be critical for patients, providers and healthcare systems.

Our study has limitations due to its retrospective nature within a single tertiary referral center. Therefore, findings may not be generalizable to all patient populations. In this study, we were unable to assess the impact of patient race because African American patients were underrepresented in our study population, which might lead to bias. In addition, analysis of nonmodifiable variables was limited to those retained within our database. Further study will assist with evaluation of other nonmodifiable patient factors which may be relevant to patient outcomes. As noted, the nonmodifiable nature of some analyzed variables is uncertain. Receipt of intraoperative transfusion, for instance, can certainly be modified in some instances and is dependent on a number of factors that could not be assessed in this review.

**Conclusion**

Nonmodifiable patient factors including age, comorbidity and intraoperative transfusion account for additional variability in perioperative outcomes of patients with RC and may factor in the development of risk-adjustment, patient counseling and reimbursement models.
Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Conflict of interest statement
The authors declare that there is no conflict of interest.

ORCID ID
Jian Chen https://orcid.org/0000-0002-6740-8401

References
1. Ljungqvist O, Scott M and Fearon K. Enhanced recovery after surgery: a review. JAMA Surg 2017; 152: 292–298.
2. Cerantola Y, Valerio M, Persson B, et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr 2013; 32: 879–887.
3. Daneshmand S, Ahmadi H, Schuckman A, et al. Enhanced recovery protocol after radical cystectomy for bladder cancer. J Urol 2014; 192: 50–55.
4. Karl A, Buchner A, Becker A, et al. A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study. J Urol 2014; 191: 335–340.
5. Di Rollo D, Mohammed A, Rawlinson A, et al. Enhanced recovery protocols in urological surgery: a systematic review. Can J Urol 2015; 22: 7817–7823.
6. Persson B, Carringer M, Andrien O, et al. Initial experiences with the enhanced recovery after surgery (ERAS) protocol in open radical cystectomy. Scand J Urol 2015; 49: 302–307.
7. Berger I, Wehrberger C, Ponholzer A, et al. Impact of the use of bowel for urinary diversion on perioperative complications and 90-day mortality in patients aged 75 years or older. Urol Int 2015; 94: 394–400.
8. Froehner M, Brausi M, Herr H, et al. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol 2009; 56: 443–454.
9. Djaladat H, Katebian B, Bazargani S, et al. 90-day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: a prospective cohort study. World J Urol 2017; 35: 907–911.
10. Chappidi M, Kates M, Patel H, et al. Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. Urol Oncol 2016; 34: 256.e1–256.e6.
11. Morgan T, Barocas D, Keegan K, et al. Volume outcomes of cystectomy: is it the surgeon or the setting? J Urol 2012; 188: 2139–2144.
12. Kulkarni G, Urbach D, Austin P, et al. Higher surgeon and hospital volume improves long-term survival after radical cystectomy. Cancer 2013; 119: 3546–3554.
13. Bhindi B, Yu J, Kuk C, et al. The importance of surgeon characteristics on impacting oncologic outcomes for patients undergoing radical cystectomy. J Urol 2014; 192: 714–719.
14. Siegel R, Miller K and Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
15. Gakis G, Efstatiiou J, Lerner S, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013; 63: 45–57.
16. Stenzl A, Cowan N, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009–1018.
17. Shabsigh A, Korets R, Vora K, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55: 164–174.
18. Maurice MJ, Ramirez D, Kara Ö, et al. Nonmodifiable factors predict discharge quality after robotic partial nephrectomy. Int Urol Nephrol 2017; 49: 37–41.
19. Larson J, Kaouk J, Stifelman M, et al. Nonmodifiable factors and complications contribute to length of stay in robot-assisted partial nephrectomy. J Endourol 2015; 29: 422–429.
20. Lee C, Madii R, Daignault S, et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 2006; 175: 1262–1267.
21. Smith A, Deal A, Yu H, et al. Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol 2014; 191: 1714–1720.
22. Sharma P, Henriksen C, Zargar-Shoshtari K, et al. Preoperative patient reported
mental health is associated with high grade complications after radical cystectomy. *J Urol* 2016; 195: 47–52.

23. Chang S, Cookson M, Baumgartner R, et al. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. *J Urol* 2002; 167: 2012–2016.

24. Djaladat H and Daneshmand S. Gastrointestinal complications in patients who undergo radical cystectomy with enhanced recovery protocol. *Curr Urol Rep* 2016; 17: 50.

25. Regenbogen S, Cain-Nielsen A, Norton E, et al. Costs and consequences of early hospital discharge after major inpatient surgery in older adults. *JAMA Surg* 2017; 152: e170123.

26. Osawa T, Ambani S, Olugbade K Jr, et al. Potential implications of shortening length of stay following radical cystectomy in a pre-ERAS population. *Urology* 2017; 102: 92–99.

27. Kaye D, Miller D and Ellimoottil C. Alternative payment models and urology. *Curr Opin Urol* 2017; 27: 360–365.